New data confirms antiviral activity of fluvastatin in patients with HCV

May 20, 2017

Thomas R. Trotter, president and CEO of AngioScore, added, "The peripheral artery disease market is one of the rapidly growing segments of the overall interventional cardiovascular market worldwide. Over 1.5 million percutaneous peripheral procedures are now being performed annually worldwide, and the growth rate is accelerating due to improved diagnosis and the increasing incidence of important risk factors, such as adult-onset diabetes mellitus. We believe that the AngioSculpt line of Scoring Balloon Catheters is particularly useful in treating this very challenging and serious disease."

The AngioSculpt Scoring Balloon Catheters represent the next generation in angioplasty balloon catheters for both coronary and peripheral artery disease. Their innovative nitinol scoring elements provide unique circumferential scoring of plaque, leading to precise and predictable luminal enlargement across a wide range of lesion types while avoiding "geographic miss" through their unique anti-slippage properties. The AngioSculpt balloon catheters provide the versatility and effectiveness of a new technology together with the simplicity and deliverability of traditional high-performance balloon catheters.

AngioSculpt devices have now been used in more than 100,000 procedures worldwide and have achieved an outstanding performance record in the treatment of both coronary and peripheral artery disease.

SOURCE AngioScore, Inc.